{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:39:34Z","timestamp":1793342374113,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02289-y","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:26:42Z","timestamp":1775194002000},"page":"871-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-6161","authenticated-orcid":false,"given":"Marzia","family":"Del Re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-3558","authenticated-orcid":false,"given":"Elvira","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-704X","authenticated-orcid":false,"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-4947","authenticated-orcid":false,"given":"Erik J.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"2289_CR1","doi-asserted-by":"crossref","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Investig. 2023;133(18).","DOI":"10.1172\/JCI172156"},{"issue":"7","key":"2289_CR2","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA. Datopotamab deruxtecan: first approval. Drugs. 2025;85(7):965\u201375.","journal-title":"Drugs"},{"key":"2289_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Martin","year":"2024","unstructured":"Martin M, Pandiella A, Vargas-Castrillon E, Diaz-Rodriguez E, Iglesias-Hernangomez T, Martinez Cano C, et al. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024;198:104355.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80(10):1019\u201325.","journal-title":"Drugs"},{"issue":"17","key":"2289_CR5","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","volume":"20","author":"L Amiri-Kordestani","year":"2014","unstructured":"Amiri-Kordestani L, Blumenthal GM, Xu QC, Zhang L, Tang SW, Ha L, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436\u201341.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2289_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhu Y, Qi D, Tang C, Zhang W. Trop2-targeted therapy in breast cancer. Biomark Res. 2024;12(1):82.","journal-title":"Biomark Res."},{"issue":"2","key":"2289_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2289_CR8","first-page":"731","volume":"6","author":"N Vey","year":"2000","unstructured":"Vey N, Giles FJ, Kantarjian H, Smith TL, Beran M, Jeha S. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin Cancer Res. 2000;6(2):731\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2289_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"issue":"12","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"2289_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","volume":"11","author":"DM Goldenberg","year":"2019","unstructured":"Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11(6):987\u201395.","journal-title":"MAbs"},{"issue":"7","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"2289_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390094","volume":"43","author":"M Shastry","year":"2023","unstructured":"Shastry M, Gupta A, Chandarlapaty S, Young M, Powles T, Hamilton E. Rise of antibody-drug conjugates: the present and future. Am Soc Clin Oncol Educ Book. 2023;43:e390094.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2289_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11523-024-01075-8","volume":"19","author":"D Moes","year":"2024","unstructured":"Moes D, Hendrikx J, Guchelaar HJ, Mathijssen RHJ, Bakker JL, Dezentje VO, et al. Model-informed development of a cost-saving dosing regimen for Sacituzumab Govitecan. Target Oncol. 2024;19(5):789\u201396.","journal-title":"Target Oncol"},{"key":"2289_CR15","doi-asserted-by":"publisher","first-page":"PS08-3Abs","DOI":"10.1158\/1538-7445.SABCS23-PS08-03","volume":"84","author":"RO Abelman","year":"2024","unstructured":"Abelman RO, Spring L, Fell G, Davis A, Hensing W, Ryan P, et al. Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis. Can Res. 2024;84:PS08-3Abs.","journal-title":"Can Res"},{"issue":"4","key":"2289_CR16","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2023;15(4):2825\u201334.","journal-title":"Cancers (Basel)."},{"key":"2289_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103067","volume":"142","author":"LFC de Almeida","year":"2026","unstructured":"de Almeida LFC, Leite LF, Cappellaro AP, da Conceicao LD, Noronha MM, da Silva JL, et al. Sequencing antibody-drug conjugates in metastatic breast cancer: a systematic review. Cancer Treat Rev. 2026;142:103067.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2289_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"S Garcia-Alonso","year":"2020","unstructured":"Garcia-Alonso S, Ocana A, Pandiella A. Trastuzumab Emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer. 2020;6(2):130\u201346.","journal-title":"Trends Cancer"},{"key":"2289_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/1538-7445.AM2023-383","volume":"83","author":"MB Nilsson","year":"2023","unstructured":"Nilsson MB, Poteete A, Udagawa H, Yu X, He J, Le X, et al. Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors. Cancer Res. 2023;83:383.","journal-title":"Cancer Res"},{"key":"2289_CR20","doi-asserted-by":"crossref","unstructured":"Kumar S, Sherman MY. Resistance to TOP-1 inhibitors: good old drugs still can surprise us. Int J Mol Sci. 2023;24(8):7233.","DOI":"10.3390\/ijms24087233"},{"issue":"10","key":"2289_CR21","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to Sacituzumab Govitecan in triple-negative breast cancer. Cancer Discov. 2021;11(10):2436\u201345.","journal-title":"Cancer Discov"},{"issue":"5","key":"2289_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/10409238.2018.1488803","volume":"53","author":"JH Guervilly","year":"2018","unstructured":"Guervilly JH, Gaillard PH. SLX4: multitasking to maintain genome stability. Crit Rev Biochem Mol Biol. 2018;53(5):475\u2013514.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"5","key":"2289_CR23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.molcel.2017.01.031","volume":"65","author":"HD Wyatt","year":"2017","unstructured":"Wyatt HD, Laister RC, Martin SR, Arrowsmith CH, West SC. The SMX DNA Repair Tri-nuclease. Mol Cell. 2017;65(5):848\u201360 (e11).","journal-title":"Mol Cell"},{"issue":"8","key":"2289_CR24","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110\u201320.","journal-title":"Nat Med"},{"issue":"1","key":"2289_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2009.06.030","volume":"138","author":"JM Svendsen","year":"2009","unstructured":"Svendsen JM, Smogorzewska A, Sowa ME, O\u2019Connell BC, Gygi SP, Elledge SJ, et al. Mammalian BTBD12\/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell. 2009;138(1):63\u201377.","journal-title":"Cell"},{"issue":"9","key":"2289_CR26","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/00498254.2018.1531158","volume":"49","author":"Y Nagai","year":"2019","unstructured":"Nagai Y, Oitate M, Shiozawa H, Ando O. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica. 2019;49(9):1086\u201396.","journal-title":"Xenobiotica"},{"issue":"1","key":"2289_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12885-022-09446-y","volume":"22","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Choi CH. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4. BMC Cancer. 2022;22(1):446.","journal-title":"BMC Cancer"},{"issue":"5","key":"2289_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1006\/bbrc.2001.4267","volume":"280","author":"S Kawabata","year":"2001","unstructured":"Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun. 2001;280(5):1216\u201323.","journal-title":"Biochem Biophys Res Commun"},{"key":"2289_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169\u201377.","journal-title":"Breast"},{"issue":"296","key":"2289_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117863","volume":"15","author":"X Zhang","year":"2025","unstructured":"Zhang X, Xiao H, Na F, Sun J, Guan Q, Liu R, et al. Evolution of TROP2: Biological insights and clinical applications. Eur J Med Chem. 2025;15(296):117863.","journal-title":"Eur J Med Chem"},{"issue":"3-4","key":"2289_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6(3\u20134):84\u2013105.","journal-title":"Genes Cancer"},{"issue":"1","key":"2289_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12885-025-14402-7","volume":"25","author":"NAA Ebrahim","year":"2025","unstructured":"Ebrahim NAA, Hussein MA, Sobeih ME, Amin NH. From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute. BMC Cancer. 2025;25(1):1008.","journal-title":"BMC Cancer"},{"issue":"2","key":"2289_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cbf.3450","volume":"38","author":"X Sun","year":"2020","unstructured":"Sun X, Xing G, Zhang C, Lu K, Wang Y, He X. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT\/beta-catenin pathway. Cell Biochem Funct. 2020;38(2):141\u20138.","journal-title":"Cell Biochem Funct"},{"issue":"Suppl_12","key":"2289_CR34","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1158\/1538-7445.AM2022-5127","volume":"82","author":"CY Liu","year":"2022","unstructured":"Liu CY, Chen JL, Chu PY, Huang CT, Wang WL, Huang CC, et al. Significance of Trop-2 in HER2-positive breast cancer. Can Res. 2022;82(Suppl_12):5127.","journal-title":"Can Res"},{"issue":"3","key":"2289_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43(3):297\u2013337.","journal-title":"Cancer Commun"},{"issue":"1","key":"2289_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM. Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther. 2023;22(1):102\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2289_CR37","doi-asserted-by":"crossref","unstructured":"Sakach E, Sacks R, Kalinsky K. Trop-2 as a Therapeutic Target in Breast Cancer. Cancers (Basel). 2022;14(23):5936.","DOI":"10.3390\/cancers14235936"},{"issue":"6","key":"2289_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100668","volume":"3","author":"I Makhlin","year":"2022","unstructured":"Makhlin I, DeMichele A. Trastuzumab deruxtecan: an antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 2022;3(6):100668.","journal-title":"Cell Rep Med."},{"issue":"9","key":"2289_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1358\/dot.2018.55.9.3039669","volume":"55","author":"KM Fenn","year":"2019","unstructured":"Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today (Barc). 2019;55(9):575\u201385.","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"2289_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","volume":"82","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82(9):979\u201387.","journal-title":"Drugs"},{"issue":"8","key":"2289_CR41","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182\u201394.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2289_CR42","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889\u2013907.","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"2289_CR43","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14(11):2089\u2013108.","journal-title":"Cancer Discov"},{"key":"2289_CR44","doi-asserted-by":"crossref","unstructured":"Najjar MK, Manore SG, Regua AT, Lo HW. Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes (Basel). 2022;13(11):2065.","DOI":"10.3390\/genes13112065"},{"issue":"20","key":"2289_CR45","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2289_CR46","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","volume":"31","author":"A Yver","year":"2020","unstructured":"Yver A, Agatsuma T, Soria JC. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. Ann Oncol. 2020;31(3):430\u20134.","journal-title":"Ann Oncol"},{"issue":"4","key":"2289_CR47","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","volume":"28","author":"RM DeVay","year":"2017","unstructured":"DeVay RM, Delaria K, Zhu G, Holz C, Foletti D, Sutton J, et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug Chem. 2017;28(4):1102\u201314.","journal-title":"Bioconjug Chem"},{"issue":"10390","key":"2289_CR48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andre","year":"2023","unstructured":"Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773\u201385.","journal-title":"Lancet"},{"issue":"8","key":"2289_CR49","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","volume":"29","author":"M Chen","year":"2024","unstructured":"Chen M, Huang R, Chen R, Pan F, Shen X, Li H, et al. Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance. Oncologist. 2024;29(8):e957\u201366.","journal-title":"Oncologist"},{"issue":"4","key":"2289_CR50","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","volume":"131","author":"F Poumeaud","year":"2024","unstructured":"Poumeaud F, Morisseau M, Cabel L, Goncalves A, Rivier C, Tredan O, et al. Efficacy of administration sequence: sacituzumab govitecan and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Br J Cancer. 2024;131(4):702\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"2289_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","volume":"11","author":"LA Huppert","year":"2025","unstructured":"Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ Breast Cancer. 2025;11(1):34.","journal-title":"NPJ Breast Cancer."},{"issue":"7","key":"2289_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105330","volume":"10","author":"P Tarantino","year":"2025","unstructured":"Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, Grinda T, et al. Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open. 2025;10(7):105330.","journal-title":"ESMO Open"},{"issue":"12","key":"2289_CR53","first-page":"P1-08","volume":"31","author":"P Tarantino","year":"2025","unstructured":"Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O\u2019Meara T, et al. Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC)\u2014retrospective study from the nationwide Flatiron database. Clin Cancer Res. 2025;31(12):P1-08.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2289_CR54","doi-asserted-by":"publisher","first-page":"P3-09-30","DOI":"10.1158\/1557-3265.SABCS24-P3-09-30","volume":"31","author":"H Chang","year":"2025","unstructured":"Chang H, Lei K, Fernandes FS, Vaish M, Movva S, Hodgdon C, et al. Sequential ADC treatments in metastatic breast cancer. Clin Cancer Res. 2025;31(12):P3-09\u201330.","journal-title":"Clin Cancer Res"},{"key":"2289_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104470","volume":"81","author":"X Peng","year":"2025","unstructured":"Peng X, Lan B, Wang J, Li Q, Wang J, Fan Y, et al. The ideal strategies of antibody\u2012drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: a multi-center real-world study. Breast. 2025;81:104470.","journal-title":"Breast"},{"issue":"3","key":"2289_CR56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-025-07818-z","volume":"214","author":"S Nezirevic","year":"2025","unstructured":"Nezirevic S, Anders C, Dent S, Bansal R, Yang LZ, Erkanli A, et al. Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer. Breast Cancer Res Treat. 2025;214(3):329\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"2289_CR57","doi-asserted-by":"crossref","unstructured":"Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med. 2025; 10.1056\/NEJMoa2508668.","DOI":"10.1056\/NEJMoa2508668"},{"key":"2289_CR58","doi-asserted-by":"crossref","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim S-B, Yam C, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study. ASCO Annual Meeting. Chicago, IL, US: J Clin Oncol; 2025. p. LBA109 Number 17_suppl.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"issue":"8042","key":"2289_CR59","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","volume":"636","author":"GS Sonke","year":"2024","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature. 2024;636(8042):474\u201380.","journal-title":"Nature"},{"key":"2289_CR60","unstructured":"Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med. 2025;10.1056\/NEJMoa2514661."},{"key":"2289_CR61","doi-asserted-by":"crossref","unstructured":"Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2025;37(2):166-79.","DOI":"10.1016\/j.annonc.2025.10.019"},{"issue":"29","key":"2289_CR62","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365\u201376.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2289_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02289-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:02:59Z","timestamp":1778860979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02289-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02289-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to update the affiliation\nDivision of Development of New Drugs for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marzia Del Re: writing\u2014review & editing, writing\u2014original draft, formal analysis, data curation, conceptualization. Elvira Inglese: writing\u2014review & editing, writing\u2014original draft, formal analysis, data curation, conceptualization. Emilio Bria: writing\u2014review & editing, writing\u2014original draft, conceptualization. Erik J. Blok: writing\u2014review & editing. Ron H.J. Mathijssen: writing\u2014review & editing, writing\u2014original draft, conceptualization. Giuseppe Curigliano: writing\u2014review & editing, writing\u2014original draft, conceptualization. Romano Danesi: writing\u2014review & editing, writing\u2014original draft, conceptualization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Marzia Del Re has received speaker\u2019s bureau\/advisor's fees from: Astra Zeneca, Astellas, Bayer, MSD, Daiichi Sankyo, Roche, Novartis, Lilly, Regeneron, Qiagen, Recordati, Qiagen, Amgen. Emilio Bria has received grants or contracts from Astra-Zeneca, Roche and honoraria for lectures from Merck-Sharp & Dome, Astra-Zeneca, Pfizer, Eli-Lilly, Bristol-Myers Squibb, Novartis, Takeda and Roche; he has been member of Data Safety Monitoring Board or Advisory Board of Merck-Sharp & Dome, Pfizer, Novartis, Bristol-Myers Squibb, Astra-Zeneca, Roche, Amgen and Celltrion. Ron H.J. Mathijssen reports relationships with Bayer AG and Novartis Pharma AG that include funding grants (all paid to the institute) and speaking and lecture fees. He reports a relationship with Servier that includes advisory board membership and funding grants, and he reports a relationship with NaDeNo Nanoscience that includes advisory board membership. He also reports funding grants from Astellas Pharma, Boehringer Ingelheim, Cristal Therapeutics, Deuter Oncology, Nordic Pharma, PamGene BV, Pfizer, Roche, and Sanofi (all paid to the institute). Giuseppe Curigliano has received research grants from Merck; has received honoraria from Ellipses Pharma; has received support for attending meetings and\/or travel from Roche\/Genentech, Pfizer, Daiichi Sankyo and AstraZeneca; has a leadership role for the ESMO, the European Society of Breast Cancer Specialists and ESMO Open; is a speakers\u2019 bureau member for Roche\/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, AstraZeneca and Exact Sciences; and has held consulting or advisory roles for Roche\/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Seagen, Guardant Health, Veracyte, Celcuity, Menarini, Merck, Exact Sciences, Blueprint Medicines and Gilead Sciences. Romano Danesi has received speaker\u2019s bureau\/advisor's fees from AstraZeneca, Amgen, Eisai, EUSA Pharma, Genzyme, Gilead Sciences, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Roche, Novartis, Pfizer, and Sanofi. All the competing interests are outside the present work. Elvira Inglese and Erik J. Blok declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, data availability, code availability"}}]}}